Ppo, A New Putiative Oncogene Related To Adenocarcinoma

Objective: The phenomenon of abnormal cytogenetic has shown that, loss of heterozygosity of the chromosome and chromosome obtained are in 1 chromosome and/or 1p36. These results suggest that there may be an important tumor suppresser gene or oncogene in this area. Upon completion of the human 1p35-1p36 genetic map, we cloned a new putative oncogene in 1p36 based on the clone screening technology, numbered KAI0090. we named the gene for PPO(Phosphorylation and Proliferation Oncogene). The initial research was shown that the PPO gene was over-expressed in a variety of cancer. Through genetic recombination, we certify that the oncogene related to proliferation and phosphorylation at the cellular level and the level of survival. Through screening of a many types tumor tissue by immunohistochemical, we find PPO gene was not detected in tumor of mesenchymal tissue and over-expressed in tumor of epithelial tissue. The immunohistochemical, RT-PCT and Western blotting is used to confirm the relationship between the PPO gene and adenocarcinoma. The results shows that the PPO gene overexpress in adenocarcinoma tissue, so it maybe a new molecular marker for the diagnosis of adenocarcinoma and a new target for therapy.Methods: All samples were from the Third Affiliated Hospital of Hebei Medical University and the Fourth Affiliated Hospital of Hebei Medical University. Samples were fixed in 10% formalin solution after surgery by HE and immunohistochemical. Samples for RT-PCT and Western blotting were fixed immediately in liquid nitrogen after surgery, stored at -80℃in ultra-low temperature freezer. All samples were confirmed by histopathology. These samples contain thyroid cancer, adenocarcinoma of lung, pulmonary squamous cell carcinoma, small cell lung carcinoma, mammary cancer, esophageal squamous cell carcinoma, carcinoma of stomach, hepatocellular carcinoma, cholangiocarcinoma, carcinoma of colon, endometrioid adenocarcinoma, prostatic carcinoma, ovarian cancer and so on.3-5 samples of each tumor were analyzed by immunohistochemical. The carcinoma of stomach, hepatocellular carcinoma, carcinoma of colon, ovarian cancer were analyzed by RT-PCR and adenocarcinoma of lung, ovarian cancer were analyzed by Western blotting.Result: PPO gene was over-expressed in thyroid cancer, adenocarcinoma of lung, mammary cancer, carcinoma of stomach, hepatocellular carcinoma, cholangiocarcinoma, carcinoma of colon, endometrioid adenocarcinoma, prostatic carcinoma, ovarian cancer. PPO gene was not detected in pulmonary squamous cell carcinoma, small cell lung carcinoma, esophageal squamous cell carcinoma, multiple myeloma, malignant fibrous histiocytoma, malignant lymphoma, malignant neurofibroma, solitary plasma cell sarcoma, malignant fibrous histiocytoma of bone, chondrosarcoma, primitive neuroectodermal tumor, adipoma. Western blotting confirmed the results of immunohistochemical. RT-PCR results show that PPO gene was overexpressed in carcinoma of stomach, hepatocellular carcinoma, carcinoma of colon, ovarian cancer, whereas was few expressed in normal tissues.Conclusion:1 PPO gene accord with the characteristics of cancer genes. RT-PCR results show that PPO gene overexpressed in carcinoma of stomach, hepatocellular carcinoma, carcinoma of colon, ovarian cancer, whereas was few expressed in normal tissues. From this we can say that, PPO gene is in normal tissues, and is overexpressed in tumor after activating, so that it is a new putative oncogene.2 PPO gene is overexpressed in adenocarcinoma of lung and is not detected in pulmonary squamous cell carcinoma, small cell lung carcinoma.3 PPO gene is weak expressed in the sample of ovarian cyst; is expressed in ovarian mucinous cystadenoma, borderline ovarian mucinous papillary cystadenoma and is over-expressed in mucinous cystadenocarcinoma of ovary, sero-papillary cancer of ovary, the expression of PPO gene with the degree of malignancy increased with the increase. 4 PPO gene overexpress in thyroid cancer, adenocarcinoma of lung, mammary cancer, carcinoma of stomach, hepatocellular carcinoma, cholangiocarcinoma, carcinoma of colon, endometrioid adenocarcinoma, prostatic carcinoma, ovarian cancer.5 PPO is not detected in esophageal squamous cell carcinoma, multiple myeloma, malignant fibrous histiocytoma, malignant lymphoma, malignant neurofibroma, solitary plasma cell sarcoma, malignant fibrous histiocytoma of bone, chondrosarcoma, primitive neuroectodermal tumor, adipoma.6 Western blotting confirmed the results of immunohistochemical, PPO gene overexpress in ovarian cancer and adenocarcinoma of lung, but is not detected in osteosarcoma.7 The results showed that the PPO gene was overexpression in adenocarcinoma tissue, so it maybe a new molecular marker for the diagnosis of adenocarcinoma and a new target for therapy.